Aurora Biosciences/PanVera Announce First Integrated Product; Launching Metabolism Screening Kits in April

Apr 11, 2001, 01:00 ET from Aurora Biosciences Corporation

    SAN DIEGO, April 11 /PRNewswire/ -- Aurora Biosciences Corporation
 (Nasdaq:   ABSC) and PanVera Corporation today announced that they plan to
 launch the first integrated product leveraging the core technologies of both
 companies in the coming weeks.  The new screening kits will be used for
 high-throughput screening of drug candidates for inhibition of cytochrome P450
 isozymes.  This class of enzymes is involved in drug metabolism and their
 inhibition can affect the efficacy and safety of potential drug candidates.
     Aurora Biosciences' Vivid(TM) Cytochrome P450 Fluorogenic Probe Substrates
 will be packaged with PanVera's highly active and specific P450 BACULOSOMES(R)
 Reagents in easy-to-use kits.  Together, the Vivid Fluorogenic Substrates and
 P450 BACULOSOMES Reagents provide a sensitive, non-radioactive, format-free,
 optimized method for the study of cytochrome P450 isozyme-drug interactions.
     Aurora's Vivid Fluorogenic Substrates offer significant advantages over
 conventional probes, including superior substrate and fluorescence properties
 and ease of use.  These probes excite in the visible light spectrum, which
 minimizes interference from test compounds and assay reagents, and they have
 improved aqueous solubility.  In addition, sets of Vivid probes with
 complementary substrate properties are available for certain key cytochrome
 P450 isozymes, permitting a more complete analysis of possible compound/P450
 enzyme interactions.
     PanVera's P450 BACULOSOMES Reagents are microsomes prepared from insect
 cells infected with recombinant baculovirus containing a cDNA insert for a
 human P450 isozyme and the accompanying NADPH-P450 reducing enzyme.  P450
 BACULOSOMES Reagents offer a distinct advantage over human liver microsomes in
 that a single P450 isozyme is expressed, thereby preventing metabolism by
 other P450s isozymes, enabling one to determine the specificity of a P450
 isozyme-drug interaction.  For additional information on the Vivid Screening
 Kits, visit the PanVera website at http://www.panvera.com
     "We are delighted to be launching the first integrated product within
 weeks of closing the Aurora/PanVera merger," stated Brian A. Pollok, Ph.D.,
 vice president, Discovery Biology.  "The metabolism screening kits are part of
 an ongoing effort to leverage the complementary technologies and products of
 the companies."
 
     Aurora Biosciences(R) develops and commercializes technologies, products
 and services to accelerate the discovery of new medicines.  Our core
 technologies include a broad portfolio of proprietary fluorescence assay
 technologies and screening platforms designed to provide an integrated
 solution for drug discovery.  Our fluorescence assay technologies include our
 GeneBLAzer(TM), GenomeScreen(TM), PhosphoryLIGHT(TM) and Vivid(TM)
 technologies, as well as a broad collection of fluorescent proteins.  Our
 screening platforms include our ultra-high throughput screening system, the
 UHTSS(R) Platform, our automated master compound store, the AMCS, and our ion
 channel technology screening platform, which includes our proprietary voltage
 sensor probes and voltage ion probe reader, the VIPR(TM) subsystem.  We also
 provide assay development and screening services as part of our drug discovery
 collaborations.  Our Big Biology(TM) Initiative is an internal drug discovery
 program focused on the identification of promising preclinical candidates
 within all major classes of gene targets.  Our technologies and drug discovery
 capabilities have been commercially validated by over 20 major life sciences
 companies and research organizations, including American Home Products,
 Bristol-Myers Squibb Co., Ceres, Inc., Cystic Fibrosis Foundation, Eli Lilly &
 Co., Families of SMA, GlaxoSmithKline, Genentech, Inc., Johnson & Johnson,
 Merck & Co., Inc., NV Organon Laboratories, Pfizer, Inc., Pharmacia and Roche,
 in the form of commercialization agreements for discovery collaborations,
 research services, licenses or systems.  For additional information on
 Aurora's services and products, please contact Sales and Marketing via email
 at marcom@aurorabio.com.
 
     Established in 1992, PanVera Corporation, a wholly-owned subsidiary of
 Aurora Biosciences Corporation, is a international leader in the development
 of products and technologies that allow pharmaceutical companies to select and
 develop new drugs more rapidly and cost-effectively.  PanVera has produced
 hundreds of recombinant proteins for commercial sale focusing on protein
 families that are of broad interest from a therapeutic perspective, including
 nuclear receptors, protein kinases and drug metabolizing enzymes.  In addition
 to recombinant proteins, PanVera provides CoreHTS(R) fluorescence
 polarization-based assays for high-throughput screening, and contract services
 in protein manufacturing, assay development and drug metabolite production.
 For additional corporate information, visit the PanVera website at
 http://www.panvera.com.
 
     Statements in this press release that are not strictly historical are
 "forward-looking" statements which involve a high degree of technological and
 competitive risks and uncertainties that exist in Aurora's operations and
 business environment.  Factors that could cause or contribute to differences
 include Aurora's ability to develop and commercialize new technologies and
 products, including our metabolism screening kits, as well as commercial
 acceptance of such technologies, Aurora's ability and products, including our
 metabolism screening kits, to rapidly identify promising drug candidates
 through its Big Biology initiative, risks associated with patent prosecution
 generally, Aurora's dependence on patents and proprietary rights, Aurora's
 ability to generate additional sales of products and services, Aurora's
 dependence on pharmaceutical and biotechnology collaborations and the
 development or availability of competing technologies, products or services.
 These factors and others are more fully described in Aurora's Annual Report on
 Form 10-K for the fiscal year ended December 31, 2000, as filed with the
 Securities and Exchange Commission.  For additional corporate information,
 visit the Aurora website at http://www.aurorabio.com.
 
     Aurora Biosciences(R), Big Biology(TM), GeneBLAzer(TM), GenomeScreen(TM),
 PhosphoryLIGHT(TM), UHTSS(R), VIPR(TM) and Vivid(TM) are trademarks of Aurora
 Biosciences Corporation.
     BACULOSOMES(R) and CoreHTS(R) are registered trademarks of PanVera
 Corporation.
 
 

SOURCE Aurora Biosciences Corporation
    SAN DIEGO, April 11 /PRNewswire/ -- Aurora Biosciences Corporation
 (Nasdaq:   ABSC) and PanVera Corporation today announced that they plan to
 launch the first integrated product leveraging the core technologies of both
 companies in the coming weeks.  The new screening kits will be used for
 high-throughput screening of drug candidates for inhibition of cytochrome P450
 isozymes.  This class of enzymes is involved in drug metabolism and their
 inhibition can affect the efficacy and safety of potential drug candidates.
     Aurora Biosciences' Vivid(TM) Cytochrome P450 Fluorogenic Probe Substrates
 will be packaged with PanVera's highly active and specific P450 BACULOSOMES(R)
 Reagents in easy-to-use kits.  Together, the Vivid Fluorogenic Substrates and
 P450 BACULOSOMES Reagents provide a sensitive, non-radioactive, format-free,
 optimized method for the study of cytochrome P450 isozyme-drug interactions.
     Aurora's Vivid Fluorogenic Substrates offer significant advantages over
 conventional probes, including superior substrate and fluorescence properties
 and ease of use.  These probes excite in the visible light spectrum, which
 minimizes interference from test compounds and assay reagents, and they have
 improved aqueous solubility.  In addition, sets of Vivid probes with
 complementary substrate properties are available for certain key cytochrome
 P450 isozymes, permitting a more complete analysis of possible compound/P450
 enzyme interactions.
     PanVera's P450 BACULOSOMES Reagents are microsomes prepared from insect
 cells infected with recombinant baculovirus containing a cDNA insert for a
 human P450 isozyme and the accompanying NADPH-P450 reducing enzyme.  P450
 BACULOSOMES Reagents offer a distinct advantage over human liver microsomes in
 that a single P450 isozyme is expressed, thereby preventing metabolism by
 other P450s isozymes, enabling one to determine the specificity of a P450
 isozyme-drug interaction.  For additional information on the Vivid Screening
 Kits, visit the PanVera website at http://www.panvera.com
     "We are delighted to be launching the first integrated product within
 weeks of closing the Aurora/PanVera merger," stated Brian A. Pollok, Ph.D.,
 vice president, Discovery Biology.  "The metabolism screening kits are part of
 an ongoing effort to leverage the complementary technologies and products of
 the companies."
 
     Aurora Biosciences(R) develops and commercializes technologies, products
 and services to accelerate the discovery of new medicines.  Our core
 technologies include a broad portfolio of proprietary fluorescence assay
 technologies and screening platforms designed to provide an integrated
 solution for drug discovery.  Our fluorescence assay technologies include our
 GeneBLAzer(TM), GenomeScreen(TM), PhosphoryLIGHT(TM) and Vivid(TM)
 technologies, as well as a broad collection of fluorescent proteins.  Our
 screening platforms include our ultra-high throughput screening system, the
 UHTSS(R) Platform, our automated master compound store, the AMCS, and our ion
 channel technology screening platform, which includes our proprietary voltage
 sensor probes and voltage ion probe reader, the VIPR(TM) subsystem.  We also
 provide assay development and screening services as part of our drug discovery
 collaborations.  Our Big Biology(TM) Initiative is an internal drug discovery
 program focused on the identification of promising preclinical candidates
 within all major classes of gene targets.  Our technologies and drug discovery
 capabilities have been commercially validated by over 20 major life sciences
 companies and research organizations, including American Home Products,
 Bristol-Myers Squibb Co., Ceres, Inc., Cystic Fibrosis Foundation, Eli Lilly &
 Co., Families of SMA, GlaxoSmithKline, Genentech, Inc., Johnson & Johnson,
 Merck & Co., Inc., NV Organon Laboratories, Pfizer, Inc., Pharmacia and Roche,
 in the form of commercialization agreements for discovery collaborations,
 research services, licenses or systems.  For additional information on
 Aurora's services and products, please contact Sales and Marketing via email
 at marcom@aurorabio.com.
 
     Established in 1992, PanVera Corporation, a wholly-owned subsidiary of
 Aurora Biosciences Corporation, is a international leader in the development
 of products and technologies that allow pharmaceutical companies to select and
 develop new drugs more rapidly and cost-effectively.  PanVera has produced
 hundreds of recombinant proteins for commercial sale focusing on protein
 families that are of broad interest from a therapeutic perspective, including
 nuclear receptors, protein kinases and drug metabolizing enzymes.  In addition
 to recombinant proteins, PanVera provides CoreHTS(R) fluorescence
 polarization-based assays for high-throughput screening, and contract services
 in protein manufacturing, assay development and drug metabolite production.
 For additional corporate information, visit the PanVera website at
 http://www.panvera.com.
 
     Statements in this press release that are not strictly historical are
 "forward-looking" statements which involve a high degree of technological and
 competitive risks and uncertainties that exist in Aurora's operations and
 business environment.  Factors that could cause or contribute to differences
 include Aurora's ability to develop and commercialize new technologies and
 products, including our metabolism screening kits, as well as commercial
 acceptance of such technologies, Aurora's ability and products, including our
 metabolism screening kits, to rapidly identify promising drug candidates
 through its Big Biology initiative, risks associated with patent prosecution
 generally, Aurora's dependence on patents and proprietary rights, Aurora's
 ability to generate additional sales of products and services, Aurora's
 dependence on pharmaceutical and biotechnology collaborations and the
 development or availability of competing technologies, products or services.
 These factors and others are more fully described in Aurora's Annual Report on
 Form 10-K for the fiscal year ended December 31, 2000, as filed with the
 Securities and Exchange Commission.  For additional corporate information,
 visit the Aurora website at http://www.aurorabio.com.
 
     Aurora Biosciences(R), Big Biology(TM), GeneBLAzer(TM), GenomeScreen(TM),
 PhosphoryLIGHT(TM), UHTSS(R), VIPR(TM) and Vivid(TM) are trademarks of Aurora
 Biosciences Corporation.
     BACULOSOMES(R) and CoreHTS(R) are registered trademarks of PanVera
 Corporation.
 
 SOURCE  Aurora Biosciences Corporation